Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10100063 | 1.00 | CYP3A4 (0.34) | CYP3A4HTTSMN1; SMN2SMYD2TRPA1 | |
| SCHEMBL10100061 | 1.00 | CYP3A4 (0.34) | CYP3A4HTTSMN1; SMN2SMYD2TRPA1 | |
| SCHEMBL12432641 | 0.92 | SMYD2 (0.36) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL12432646 | 0.92 | SMYD2 (0.36) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL18082175 | 0.88 | SMYD2 (0.35) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL4264816 | 0.87 | CYP3A4 (0.38) | CYP3A4HTTSMN1; SMN2SMYD2TRPA1 | |
| SCHEMBL18047522 | 0.85 | SMYD2 (0.36) | CYP3A4HTTSMN1; SMN2SMYD2TRPA1 | |
| SCHEMBL18047524 | 0.85 | SMYD2 (0.36) | CYP3A4HTTSMN1; SMN2SMYD2TRPA1 | |
| SCHEMBL14574000 | 0.84 | CYP3A4 (0.37) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL5155697 | 0.84 | CYP3A4 (0.37) | CYP3A4HTTSMN1; SMN2SMYD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11643418-B2 | Macrocyclization reactions and intermediates and other fragments useful in the synthesis of analogs of halichondrin B | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-05-09 | — | — | US | disclosed |
| US-11643418-B2 | Macrocyclization reactions and intermediates and other fragments useful in the synthesis of analogs of halichondrin B | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-05-09 | — | — | US | disclosed |
| CN-114716453-A | Macrocyclization reactions and intermediates useful in the synthesis of analogs of halichondrin B | 卫材R&D管理有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-109942560-B | Macrocyclization reactions and intermediates useful in the synthesis of analogs of halichondrin B | 卫材R&D管理有限公司 | 2022-06-17 | — | — | CN | disclosed |
| EP-3689881-B1 | MACROCYCLIZATION REACTIONS AND INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANALOGS OF HALICHONDRIN B | EISAI R&D MAN CO LTD (JP) | 2022-01-12 | — | — | EP | disclosed |
| US-20210188867-A1 | MACROCYCLIZATION REACTIONS AND INTERMEDIATES AND OTHER FRAGMENTS USEFUL IN THE SYNTHESIS OF ANALOGS OF HALICHONDRIN B | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-06-24 | — | — | US | disclosed |
| US-10934307-B2 | Macrocyclization reactions and intermediates and other fragments useful in the synthesis of analogs of halichondrin B | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-03-02 | — | — | US | disclosed |
| EP-3689881-A1 | MACROCYCLIZATION REACTIONS AND INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANALOGS OF HALICHONDRIN B | Eisai R&D Management Co., Ltd. (JP) | 2020-08-05 | — | — | EP | disclosed |
| US-20200223864-A1 | MACROCYCLIZATION REACTIONS AND INTERMEDIATES AND OTHER FRAGMENTS USEFUL IN THE SYNTHESIS OF ANALOGS OF HALICHONDRIN B | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-07-16 | — | — | US | disclosed |
| US-10611773-B2 | Macrocyclization reactions and intermediates and other fragments useful in the synthesis of analogs of halichondrin B | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-04-07 | — | — | US | disclosed |
| US-RE45324-E1 | Intermediates for the preparation of analogs of halichondrin B | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-01-06 | — | — | US | disclosed |
| US-8884031-B2 | Intermediates for the preparation of analogs of halichondrin B | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-11-11 | — | — | US | disclosed |
| US-20140221635-A1 | INTERMEDIATES FOR THE PREPARATION OF ANALOGS OF HALICHONDRIN B | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20140163242-A1 | INTERMEDIATES FOR THE PREPARATION OF ANALOGS OF HALICHONDRIN B | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-06-12 | — | — | US | disclosed |
| US-20130237711-A1 | INTERMEDIATES FOR THE PREPARATION OF ANALOGS OF HALICHONDRIN B | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-09-12 | — | — | US | disclosed |
| US-8445701-B2 | Intermediates for the preparation of analogs of halichondrin B | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-05-21 | — | — | US | disclosed |
| US-20120309988-A1 | INTERMEDIATES FOR THE PREPARATION OF ANALOGS OF HALICHONDRIN B | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-12-06 | — | — | US | disclosed |
| US-20120029213-A1 | INTERMEDIATES FOR THE PREPARATION OF ANALOGS OF HALICHONDRIN B | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-02-02 | — | — | US | disclosed |
| US-7982060-B2 | Intermediates for the preparation of analogs of Halichondrin B | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-07-19 | — | — | US | disclosed |
| US-20070244187-A1 | Intermediates for the Preparation of Halichondrin B | EISAI CO., LTD (JP) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244187-A1 | Intermediates for the Preparation of Halichondrin B | CDK4, CCNB1, CDK14 | CYP3A4 910/4885HTT 1134/4885SMN1; SMN2 2707/4885 |
| US-20130237711-A1 | INTERMEDIATES FOR THE PREPARATION OF ANALOGS OF HALICHONDRIN B | DHPS, BMP2, CDK11B | CYP3A4 3206/4885HTT 2309/4885SMN1; SMN2 2374/4885 |
| US-20200223864-A1 | MACROCYCLIZATION REACTIONS AND INTERMEDIATES AND OTHER FRAGMENTS USEFUL IN THE SYNTHESIS OF ANALOGS OF HALICHONDRIN B | ERLIN1, MAN1B1, DHPS | CYP3A4 1097/4885HTT 1329/4885SMN1; SMN2 3712/4885 |
| US-20140221635-A1 | INTERMEDIATES FOR THE PREPARATION OF ANALOGS OF HALICHONDRIN B | ACVR1B, ACVR2B, BMP2 | CYP3A4 1831/4885HTT 1888/4885SMN1; SMN2 966/4885 |
| US-10934307-B2 | Macrocyclization reactions and intermediates and other fragments useful in the synthesis of analogs of halichondrin B | ERLIN1, MAN1B1, DHPS | CYP3A4 1097/4885HTT 1329/4885SMN1; SMN2 3712/4885 |
| US-11643418-B2 | Macrocyclization reactions and intermediates and other fragments useful in the synthesis of analogs of halichondrin B | ERLIN1, MAN1B1, DHPS | CYP3A4 1735/4885HTT 877/4885SMN1; SMN2 3443/4885 |
| US-10611773-B2 | Macrocyclization reactions and intermediates and other fragments useful in the synthesis of analogs of halichondrin B | ERLIN1, MAN1B1, DHPS | CYP3A4 1097/4885HTT 1329/4885SMN1; SMN2 3712/4885 |
| US-20210188867-A1 | MACROCYCLIZATION REACTIONS AND INTERMEDIATES AND OTHER FRAGMENTS USEFUL IN THE SYNTHESIS OF ANALOGS OF HALICHONDRIN B | ERLIN1, MAN1B1, DHPS | CYP3A4 1735/4885HTT 877/4885SMN1; SMN2 3443/4885 |
| US-20120029213-A1 | INTERMEDIATES FOR THE PREPARATION OF ANALOGS OF HALICHONDRIN B | DHPS, BMP2, CDK11B | CYP3A4 3206/4885HTT 2309/4885SMN1; SMN2 2374/4885 |
| US-20120309988-A1 | INTERMEDIATES FOR THE PREPARATION OF ANALOGS OF HALICHONDRIN B | ACVR1B, ACVR2B, BMP2 | CYP3A4 1831/4885HTT 1888/4885SMN1; SMN2 966/4885 |
| US-20140163242-A1 | INTERMEDIATES FOR THE PREPARATION OF ANALOGS OF HALICHONDRIN B | DHPS, BMP2, CDK11B | CYP3A4 3206/4885HTT 2309/4885SMN1; SMN2 2374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.